Qiagen NV Dossier - Source-backed chat

Qiagen NV

QGENNYSE

SectorHealth Care

IndustryDiagnostics & Research

Beta (adjusted)0.75

Intrinsic Value $44.29median of 6 methods · middle span $42-$53based on filings through 31 Dec 2025

Market Price $42.04Price as of 1 Oct 2026

Near fair valueIntrinsic value is 5% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $8.7B

Enterprise Value $9.5B

Shares Outstanding 218.9M diluted

Moat Rating Narrow

Next Earnings Date4 Nov 2026

Last ex-dividend7 Jul 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

QIAGEN N.V. is a high-quality molecular diagnostics and life sciences tools provider currently navigating a transitional phase. While the company boasts highly recurring consumable revenues and a strong portfolio of growth pillars (such as QIAcuity digital PCR and Sample Technologies), near-term growth has rebased lower. Headwinds from a sharp decline in QuantiFERON immigration testing demand and cautious spending among U.S. Life Sciences customers forced management to lower its FY 2026 sales growth outlook to 1-2% CER. However, the downside is protected by robust profitability (targeting an adjusted operating margin near 30%), active capital returns (including a $500 million synthetic share repurchase in early 2026 and a newly introduced dividend), and an ongoing strategic alternatives review with Goldman Sachs and Moelis. With the stock trading near its fair value and potential takeover interest providing a valuation floor, a Hold recommendation is warranted pending the outcome of the strategic review and the stabilization of latent TB testing demand.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets14 analysts · as of 18 Aug 2026

Low · most bearish analyst$40.00

Mean target$46.07

High · most bullish analyst$50.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The strategic review ends with no transaction, leading to near-term 'deal fatigue' and a sell-off of the speculative premium. Concurrently, Roche's entry into the latent tuberculosis testing market accelerates market share erosion for QuantiFERON. Cautious spending in U.S. Life Sciences persists, causing QIAGEN to miss its revised FY 2026 targets and delaying its path to the $2 billion growth pillar sales target by 2028.

Base CaseCentral scenario

The strategic review concludes with QIAGEN remaining independent or pursuing minor partnerships rather than a full sale. Organic sales growth recovers in the second half of 2026 as headwinds from discontinued products (NeuMoDx and Dialunox) fade and the Parse acquisition scales. QuantiFERON sales stabilize, and the company achieves its revised FY 2026 guidance of 1-2% CER sales growth and adjusted diluted EPS of at least $2.43 CER. Valuation multiples remain steady, supported by solid free cash flow generation and disciplined capital allocation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Highly recurring revenue profile with consumables and related services representing approximately 90% of total sales.
Strong profitability and cash generation, with adjusted operating margins expanding to 29.5% in 2025 and free cash flow reaching $453 million.
Active capital allocation, returning over $1.1 billion to shareholders since 2024 through synthetic share repurchases and dividends.
Valuation support and upside optionality from the ongoing formal review of strategic alternatives.

Key Investment Risks

Looming competitive threat in the latent tuberculosis testing market as major players like Roche prepare to launch competing assays.
Near-term growth deceleration, with FY 2026 sales growth guidance revised downward to 1-2% CER due to lower immigration testing demand.
Risk of 'deal fatigue' and downward share price pressure if the strategic review concludes without a sale or major transaction.

Thesis Invalidation Triggers

A formal announcement terminating the strategic alternatives review without any transaction or structural changes.
A material downward revision of the 2028 growth pillar sales target of $2.0 billion.
Faster-than-expected market adoption of competing latent TB tests, leading to double-digit declines in QuantiFERON sales.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.